This inventor holds 1 USPTO granted patent. Top assignee: Amalive Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Carmen Mak and Her Patent on Ornithine Phenylacetate
Introduction
Carmen Mak is an inventor associated with Hampton, New Jersey, and Amalive Limited. Her patent work focuses on a treatment approach for hyperammonemia, a condition involving elevated ammonia levels in the blood.
Latest Patents
Mak is listed as an inventor on 1 patent: “Dosages and Uses of Ornithine Phenylacetate for Treating Hyperammonemia.” The disclosure describes doses and methods of administering ornithine phenylacetate to treat or ameliorate hyperammonemia in patients with chronic liver disease, such as cirrhosis. Some embodiments also address patients with hepatic encephalopathy as a complication of liver disease.
Career Highlights
Mak’s patent activity reflects work on pharmaceutical dosing and treatment methods related to chronic liver disease and its complications. The patent identifies Amalive Limited as her associated company.
Collaborations
The provided information names Xiaofeng Wang Rears and Jack Tseng as Mak’s coworkers. Their specific roles in the patent or related work are not stated.
Conclusion
Carmen Mak’s recorded patent contribution centers on ornithine phenylacetate dosing and administration for hyperammonemia, including cases associated with chronic liver disease.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile